Citius Pharmaceuticals (CTXR) Intangibles (2014 - 2025)
Citius Pharmaceuticals' (CTXR) quarterly Intangibles came in at $72.8 million in Q4 2025, up 275.39% on a QoQ basis from $19.4 million in Q1 2017.
Citius Pharmaceuticals (CTXR) Intangibles (2014 - 2025) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 5 years of Intangibles data on file, last reported at $72.8 million in Q4 2025.
- Quarterly Intangibles changed N/A year-over-year to $72.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $72.8 million (changed N/A YoY) and the FY2015 annual result came in at $5401.0, changed 0.0% from the prior year.
- Intangibles improved to $72.8 million in Q4 2025, from $19.4 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $72.8 million in Q4 2025 to a low of $72.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Citius Pharmaceuticals | 15.89 Mn | 15.89 Mn | 1.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 72.83 Mn |
| Mar 31, 2017 | 19.40 Mn |
| Dec 31, 2016 | 19.40 Mn |
| Mar 30, 2016 | 19.40 Mn |
| Dec 31, 2015 | 5,401.00 |
| Sep 30, 2015 | 5,401.00 |
| Jun 30, 2015 | 5,401.00 |
| Mar 31, 2015 | 5,401.00 |
| Dec 31, 2014 | 5,401.00 |
| Sep 30, 2014 | 5,401.00 |